A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder
Latest Information Update: 30 Dec 2019
At a glance
- Drugs Rapastinel (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms RAP-MD-02
- Sponsors Allergan
- 06 Mar 2019 According to an Allergan media release, primary endpoint (Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at the End of Trial) has not been met.
- 06 Mar 2019 Results from trials (RAP-MD-01,-02,-03), published in an Allergan Media Release.
- 12 Dec 2018 Status changed from active, no longer recruiting to completed.